Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07061847 · ClinicalTrials.gov registry record · Phase 2

Bilateral Middle Meningeal Artery Lidocaine Infusion for Chronic Debilitating Migraines

A Phase 2 study of Migraine, sponsored by Northwell Health.

Recruiting
Registry status
Phase 2
Development phase
40
Enrollment target
1
Study location

NCT07061847: Recruiting Phase 2 study of Migraine, sponsored by Northwell Health.

NCT07061847 is a Phase 2 study of Migraine that is actively recruiting participants, run by Northwell Health. The registered enrollment target is 40 participants, below the 358-participant average among 102 other Migraine trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07061847, a Phase 2 study of Migraine, is actively recruiting participants, sponsored by Northwell Health.

RECRUITING
Registry status
Phase 2
Development phase
40 participants
Enrollment target
1
Study location

Study Summary

The main purpose of this study is to evaluate the effectiveness of a new treatment in improving chronic migraine symptoms. This treatment involves a targeted lidocaine infusion into blood vessels in the skull to numb pain receptors, potentially leading to improvements in chronic migraine intensity, frequency, and duration.

Primary Outcome

To observe a ≥50% reduction in monthly migraine headache days in one month post intra-arterial lidocaine infusion into the bilateral middle meningeal artery.

Conditions Studied

Interventions

  • DRUG Lidocaine (drug)
  • PROCEDURE Lidocaine Procedure

Study Locations (1)

New York

  • Neuroscience Institute at Great Neck - Great Neck

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2025-03-10
Est. Completion 2027-06-30
Phase Phase 2
Northwell Health

370 total trials

What NCT07061847 shows while recruiting

NCT07061847 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 358-participant average among 102 other Migraine trials with a reported enrollment target (89% lower).

The record links to 1 condition, with Migraine appearing as the primary indexed condition, and to 2 interventions - of which Lidocaine (drug) is the first listed.

NCT07061847 reports a single indexed study location in New York.

Frequently Asked Questions

What is clinical trial NCT07061847 about?

NCT07061847 is a clinical study titled "Bilateral Middle Meningeal Artery Lidocaine Infusion for Chronic Debilitating Migraines". The main purpose of this study is to evaluate the effectiveness of a new treatment in improving chronic migraine symptoms. This treatment involves a targeted lidocaine infusion into blood vessels in the skull to numb pain receptors, potentially leading to improvements in chronic migraine intensity, ...

What is the current status of trial NCT07061847?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2025-03-10. Estimated completion is 2027-06-30.

What conditions does trial NCT07061847 study?

This clinical trial studies the following conditions: Migraine.

What interventions are being tested in trial NCT07061847?

The interventions under investigation include: Lidocaine (drug) (DRUG), Lidocaine Procedure (PROCEDURE).

Who is sponsoring clinical trial NCT07061847?

This trial is sponsored by Northwell Health, which has 370 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07061847 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Migraine

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT07061847's enrollment target sits among peer trials

40 87th of 102 higher than 15 of 102 other Migraine trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Migraine trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01306019 · 40 participants · Phase 1

    Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)

  • NCT01608152 · 40 participants

    Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors

  • NCT01668082 · 40 participants · NA

    An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection

  • NCT02015013 · 40 participants · Phase 2

    Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07061847, the US trial registry maintained by the National Library of Medicine. NCT07061847 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.